Incyte Corporation (INCY)
-NasdaqGS 23.04 
0.13(0.56%) May 17, 4:00PM EDT|After Hours
:
23.11 0.07 (0.32%) May 17, 4:10PM EDT
| Prev Close: | 23.17 |
|---|
| Open: | 23.26 |
|---|
| Bid: | 18.22 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 25.21 |
|---|
| Beta: | 1.34 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 22.74 - 23.43 |
|---|
| 52wk Range: | 15.43 - 26.30 |
|---|
| Volume: | 809,187 |
|---|
| Avg Vol (3m): | 1,306,170 |
|---|
| Market Cap: | 3.13B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.11 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Incyte's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and Upcoming Deadline -- INCYGlobeNewswire(Fri, May 10)
- INCYTE CORP FinancialsEDGAR Online Financials(Fri, May 10)
- Is the Biggest Pharma Company in the World the Best Investment?at Motley Fool(Tue, May 7)
- Alnylam Narrows Loss, Sales FallZacks(Tue, May 7)
- Incyte coverage resumed with a Sell at Goldmantheflyonthewall.com(Tue, May 7)
- Arena Pharma Narrows LossZacks(Mon, May 6)
- 5 Healthcare Stock Earnings Snapshotsat Wall St. Cheat Sheet(Sat, May 4)
- Narrower-Than-Expected Loss at IncyteZacks(Fri, May 3)
- Drug Manufacturers and the FDA Collaborate More Closely for Faster Drug Approval: An Exclusive Interview with an Expert Equity Analyst Reveals Some Top Stock Picks in This Vital IndustryWall Street Transcript(Fri, May 3)
- Incyte to Present at Upcoming Investor ConferencesBusiness Wire(Fri, May 3)
- SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff DeadlineBusiness Wire(Thu, May 2)
- Incyte's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
- Incyte Earnings: Here’s Why Investors are Not Happy Nowat Wall St. Cheat Sheet(Thu, May 2)
- Incyte Corporation Earnings Call scheduled for 8:30 am ET todayCCBN(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | 230.40 |
|---|
| P/S (ttm): | 9.48 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.14 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.08 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -1.77 |
|---|
Business Summary
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation.
View More